[1] Mesinovic J,Fyfe J J,Talevski J,et al. Type 2 diabetes mellitus and sarcopenia as comorbid chronic diseases in older adults:established and emerging treatments and therapies[J]. Diabetes Metab J,2023,47(6):719-742. [2] Régnier M,Carbinatti T,Parlati L,et al. The role of ChREBP in carbohydrate sensing and NAFLD development[J]. Nat Rev Endocrinol,2023,19(6):336-349. [3] Mosenzon O,Alguwaihes A,Leon J L A,et al. CAPTURE:a multinational,cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries[J]. Cardiovasc Diabetol,2021,20(1):154-167. [4] Cai J J,Zhang X J,Ji Y X,et al. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases[J]. Circ Res,2020,126(5):679-704. [5] 叶斌,季晓珍,朱向盈,等. 血清血尿酸及甲状腺激素与2型糖尿病患者发生动脉粥样硬化性心血管疾病的关系[J]. 广东医学,2024,45(6):744-750. [6] 严凤琴,聂谷乔,周念历,等. 非酒精性脂肪性肝病及肥胖与ASCVD高风险的关系探讨[J]. 中华全科医师杂志,2023,22(5):474-479. [7] 代谢中心学术委员会,代谢中心专家顾问委员会,代谢中心理事会,等. 国家标准化代谢性疾病管理中心(MMC)代谢病管理指南(第二版)[J]. 中华内分泌代谢杂志,2023,39(6):538-554. [8] Hu Y H,Han Y,Liu Y F,et al. A nomogram model for predicting 5-year risk of prediabetes in Chinese adults[J]. Sci Rep,2023,13(1):22523-22530. [9] 宋江南,张丹丹,才蕊,等. MMC模式下2型糖尿病患者微血管并发症列线图预测模型的构建[J]. 实用预防医学,2024,31(6):678-684. [10] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志,2018,38(4):292-344. [11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 实用肝脏病杂志,2018,21(2):177-186. [12] 中国心血管病预防指南(2017)写作组,中华心血管病杂志编辑委员会. 中国心血管病预防指南(2017)[J]. 中华心血管病杂志,2018,46(1):10-25. [13] Goff D C Jr,Lloyd-Jones D M,Bennett G,et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk:a report of the American College of Cardiology/American Heart association task force on practice guidelines[J]. Circulation,2014,129(25):49-73. [14] Ferguson D,Finck B N. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus[J]. Nat Rev Endocrinol,2021,17(8):484-495. [15] Li K,Cao B,Dong H,et al. Trajectories of glycated hemoglobin of T2DM and progress of arterial stiffness:a prospective study[J]. Diabetol Metab Syndr,2023,15(1):135-140. [16] 王卫庆,王桂侠,王颜刚,等. 国家标准化代谢性疾病管理中心建设规范及管理指南[J]. 中华内分泌代谢杂志,2019,35(11):907-926. [17] 王铎霖,刘乙君,李萍,等. 估算的肾小球滤过率轻度下降与白蛋白尿对2型糖尿病患者心血管疾病风险的交互作用研究[J]. 中华糖尿病杂志,2024,16(7):746-754. [18] Yanai H,Adachi H,Hakoshima M,et al. Postprandial hyperlipidemia:its pathophysiology, diagnosis, atherogenesis, and treatments[J]. Int J Mol Sci,2023,24(18):13942-13949. [19] 刘士贺,刘倩,韩旭,等. 血浆致动脉粥样硬化指数轨迹与动脉粥样硬化性心血管疾病的关联[J]. 中国循环杂志,2024,39(7):676-681. [20] Han Y T,Zhou Z L,Zhang Y G,et al. The association of surrogates of insulin resistance with hyperuricemia among middle-aged and older individuals:a population-based nationwide cohort study[J]. Nutrients,2023,15(14):3139-3146. [21] Li F D,Wang Y,Shi B Q,et al. Association between the cumulative average triglyceride glucose-body mass index and cardiovascular disease incidence among the middle-aged and older population:a prospective nationwide cohort study in China[J]. Cardiovasc Diabetol,2024,23(1):16-22. [22] Xia X,Chen S H,Tian X,et al. Association of triglyceride-glucose index and its related parameters with atherosclerotic cardiovascular disease:evidence from a 15-year follow-up of Kailuan cohort[J]. Cardiovasc Diabetol,2024,23(1):208-219. [23] Soares C,Kwok M,Boucher K A,et al. Performance of cardiovascular risk prediction models among people living with HIV:a systematic review and meta-analysis[J]. JAMA Cardiol,2023,8(2):139-149. [24] Yi T C,Gao L,Fan F F,et al. Association between pulse wave velocity and the 10-year risk of atherosclerotic cardiovascular disease in the Chinese population:a community-based study[J]. J Clin Hypertens (Greenwich),2023,25(3):278-285. [25] 史会连,田文君,刘丽娜,等. 非酒精性脂肪性肝病患者动脉粥样硬化性心血管疾病的影响因素研究[J]. 实用心脑肺血管病杂志,2019,27(4):25-28. [26] Lv J P,Ren H,Guo X M,et al. Nomogram predicting bullying victimization in adolescents[J]. J Affect Disord,2022,44(1):264-272. |